Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Intravenous, Dose‐Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus
Jacek C. Szepietowski(Wroclaw Medical University), Benjamin Hsu(Janssen (United States)), Robert Gordon(Janssen (United States)), Adam Reich(Rzeszów University of Technology), Anna Woźniacka(National Institute of Oncology), Dick E. de Vries(Janssen (Netherlands)), Annegret Kuhn(University of Passau), Filippa Nyberg(Karolinska Institutet), Donald W. Robinson(Janssen (Belgium)), Bart van Hartingsveldt(Janssen (Netherlands)), Ronald van Vollenhoven(Amsterdam University Medical Centers), Anders Bengtsson(Lund University), Surasak Nilganuwong(Siriraj Hospital)
Cited by 115
Related Papers
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726